Crossmark

A cascading activity-based probe sequentially targets E1–E2–E3 ubiquitin enzymes

Crossref DOI link: https://doi.org/10.1038/nchembio.2084

Published Online: 2016-05-16

Published Print: 2016-07

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Mulder, Monique P C

Witting, Katharina

Berlin, Ilana

Pruneda, Jonathan N

Wu, Kuen-Phon https://orcid.org/0000-0002-1525-6004
Chang, Jer-Gung

Merkx, Remco

Bialas, Johanna

Groettrup, Marcus

Vertegaal, Alfred C O

Schulman, Brenda A

Komander, David

Neefjes, Jacques

El Oualid, Farid

Ovaa, Huib
License Information

Text and Data Mining valid from 2016-05-16
More Information

Article History

Received: 14 January 2016

Accepted: 22 March 2016

First Online: 16 May 2016

Competing interests

: H.O., M.P.C.M. and F.E.O. are entitled to royalties that may result from licensing patent application WO2016/032332 according to IP policies of the Netherlands Cancer Institute. H.O. and F.E.O. declare competing financial interests as cofounders and shareholders of UbiQ Bio BV. D.K. and H.O. are part of the DUB Alliance, which includes Cancer Research Technology and FORMA Therapeutics. D.K. is a consultant for FORMA Therapeutics.